drugset / Trial / NCT07283640
A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia
Phase 1
Not yet recruiting
20 enrolled
M.D. Anderson Cancer Center
Amgen · collabSyndax Pharmaceuticals · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To learn about the safety and effects of revumenib in combination with blinatumomab in patients with newly diagnosed or relapsed/refractory Ph-negative ALL with a KMT2A rearrangement.
Timeline
- Start
- 2026-11-18
- Primary completion
- 2029-08-31
- Completion
- 2031-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Blinatumomab | Monoclonal antibody | — | Intravenous |
| Subject | Revumenib | Small molecule | — | Oral |